In addition to providing access to therapies in early phase human clinical trials, NMDTI conducts tissue-agnostic targeted-agent studies. These studies look at treatments developed to target specific abnormalities of a disease’s genetic code, and then identify other diseases that share the same genetic targets, even if they may appear to be different clinically. If a disease does share the same genetic targets as another that has a treatment designed to interact with those same genetic targets, NMDTI wants to see if it may also be treatable using the same approach.
Focused on accelerating the translation of preclinical science breakthroughs into better therapies for patients, NMDTI was established with support from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, and Northwestern Memorial Hospital.
To learn more about NMDTI and how to enroll in a developmental therapeutics clinical trial, call 312-472-1234 or visit them online.